Proteomics Study of Gastric Bypass Surgery to Treat Type 2 Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01870713|
Recruitment Status : Unknown
Verified June 2013 by No. 150 Central Hospital of the Chinese People Liberation Army.
Recruitment status was: Active, not recruiting
First Posted : June 6, 2013
Last Update Posted : June 6, 2013
|Condition or disease|
|Type 2 Diabetes|
Diabetes Mellitus is a major global problem which responsibles for 4.6 million deaths each year without effective therapy methods. Recently，researchers showed that type 2 diabetes mellitus can be partly reversed by gastric bypassing surgery. However, surgeons are still not clear how to chose the proper diabetes patients for surgery as the mechanism is still not clear, and the remission rate of diabetes mellitus is not the same among different surgical procedures.
This study will enroll type 2 diabetes mellitus patients follwing Roux-en-Y gastric bypassing surgery and obese persons without type 2 diabetes surgery. The defferent expressions of serum proteins of obese persons without type 2 diabetes and type 2 diabetes patients following gastric bypassing surgery after 10 days or 3 months were detected by serum proteomics. Blood samples and urine will be taken prior to surgery, 10 days after surgery and 3 months after surgery. The long term prognosis of diabetes mellitus for 1 years and the remission rate of diabetes of patients will be evaluated.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||50 participants|
|Observational Model:||Case Control|
|Target Follow-Up Duration:||1 Year|
|Official Title:||Serum Proteomics Research in Bypassing Surgery to Treat Type 2 Diabetes in China|
|Study Start Date :||October 2010|
|Actual Primary Completion Date :||October 2012|
|Estimated Study Completion Date :||October 2013|
type 2 diabetes patients with gastric bypass surgery.
Participants who have type 2 diabetes and with decreased glucose after gastric bypass surgery.
Weight matched non-operated controls
Participants who are overweight to moderately obese, and have no personal of family history of Type 1, Type 2, or Gestational Diabetes.
- different proteins detected between obese persons, type 2 diabetes patients prior to surgery, 10 days after surgery and 3 months after surgery. [ Time Frame: base line to 3 months ]
- evaluating the change in glucose between the baseline evaluation and the follow-up evaluation. [ Time Frame: 1 year ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01870713
|No. 150 Central hospital of Chinese People's Liberation Army|
|Luoyang, Henan, China, 471000|